A5013889832- Acute Ischemic Stroke Management
- Stroke Rehabilitation and Recovery
- Cerebrovascular and Carotid Artery Diseases
- Venous Thromboembolism Diagnosis and Management
- Intracerebral and Subarachnoid Hemorrhage Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Imaging and Diagnostics
- Atrial Fibrillation Management and Outcomes
- Blood Coagulation and Thrombosis Mechanisms
National Clinical Research Center for Digestive Diseases
2023-2025
Capital Medical University
2023-2024
Beijing Tian Tan Hospital
2023-2024
National Clinical Research
2024
First Affiliated Hospital of Jinan University
2024
Harbin Medical University
2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2024
Tenecteplase is an effective thrombolytic agent for eligible patients with stroke who are treated within 4.5 hours after the onset of stroke. However, data regarding effectiveness tenecteplase beyond limited.
Background The benefit–risk profile of tenecteplase in the elderly patients with acute ischaemic stroke (AIS) is uncertain. We sought to investigate efficacy and safety 0.25 mg/kg compared alteplase for AIS aged ≥80 years. Methods performed a post hoc analysis Tenecteplase Reperfusion Therapy Acute Ischaemic Cerebrovascular Events-2 Trial, randomised, phase 3, non-inferiority clinical trial. Disabling years who initiated intravenous thrombolytics within 4.5 hours symptom onset were enrolled...
Importance Trials have not demonstrated superiority of alteplase or tenecteplase vs standard care in patients with mild stroke and raised safety concerns. Prourokinase is an alternative fibrinolytic that may a favorable profile, the benefit-risk profile prourokinase unknown. Objective To investigate efficacy ischemic within 4.5 hours symptom onset. Design, Setting, Participants This was multicenter, prospective, open-label, blinded–end point randomized clinical trial conducted from November...
Abstract Aim Our study aimed to explore the effectiveness and safety of intravenous t‐PA compared with dual antiplatelet therapy (DAPT) aspirin alone for minor stroke National Institutes Health Stroke Scale (NIHSS) score ≤5 large vessel occlusion (LVO). Methods Patients harboring LVO within 4.5‐h time window were included from Third China Registry (CNSR‐III) between August 2015 March 2018 in China. Clinical outcomes including modified Rankin scale (mRS) score, recurrent stroke, all‐cause...
Abstract Aims Our study aimed to describe the short‐, medium‐, and long‐term outcomes of intravenous thrombolysis in minor stroke, explore relationship between clinical outcomes. Methods included ischemic stroke patients (National Institutes Health Stroke Scale score ≤ 5) within 4.5 h from symptom onset Third China National Registry (CNSR‐III) August 2015 March 2018. The primary outcome was a favorable functional outcome, defined as modified Rankin (mRS) 0–1 at 3 months. secondary mRS...
Recombinant human prourokinase (rhPro-UK) is a new generation of specific plasminogen activator, that non-inferior to alteplase in acute ischemic stroke. We aimed investigate the efficacy and safety rhPro-UK compared with standard medical treatment mild stroke within 4.5 hours symptom onset.
Mild acute ischemic stroke (AIS) patients with large vessel occlusion (LVO) may benefit from thrombolysis or thrombectomy therapy. However, the predictors for LVO in mild AIS have not been extensively explored. We aimed to investigate patients.We collected data of consecutive a National Institutes Health Stroke Scale (NIHSS) score ≤ 5 The Third China Registry - prospective nationwide registry transient attack (TIA) August 2015 March 2018. Patients were divided into and non-LVO group based on...
Nonvalvular atrial fibrillation (NVAF) is a risk factor for stroke. This study was undertaken to determine the influence of NVAF on mortality and recurrent stroke after minor event.Data were derived from Third China National Stroke Registry (CNSR-III) which enrolled 15,166 subjects during August 2015 through March 2018 in China. Patients with (NIHSS ≤ 5) within 24 h onset included. Clinical outcomes including all-cause mortality, cardiovascular death, ischemic stroke, hemorrhagic collected....